Linkers Industries (NASDAQ:LNKS) Stock, Quote.Headers.trade-ideas

Linkers Industries Ltd is a company which acts as a manufacturer and a supplier of wire, cable harnesses with their manufacturing operations in Malaysia. Wire/cable harness refers to an assembly of wires/cables bound together with straps, cable ties and electrical tapes to transmit signals or electrical power. Company works closely with customers in each stage of a product's life cycle, including design, prototyping and production. Geographically company provides services in Thailand, Malaysia, Switzerland, United States of America, and many others, maximum revenue gained from Thailand.

Linkers Industries Limited - Class A Ordinary Shares

Linkers Industries Ltd

- Advancing robust clinical pipeline of novel therapeutics for serious muscular dystrophies and cardiac conditions -
- Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) -
Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the Annual J.P. Morgan Healthcare Conference.
"We were pleased with our progress in 2024 as we advanced our drug pipeline and have great momentum heading into 2025. With positive Phase 2 results and enrollment nearing completion in our pivotal cohort for individuals with Becker muscular dystrophy, we are optimistic about the potential of sevasemten," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise Therapeutics. "Additionally, we are thrilled with initial results from EDG-7500 in patients with obstructive hypertrophic cardiomyopathy and look forward to sharing additional, longer-term data across HCM populations in 2025."
2025 Priorities
Muscular Dystrophy Program
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder.
<ul>
<li>Complete recruitment of the GRAND CANYON pivotal placebo-controlled cohort in the first quarter of 2025</li>
<li>Seek end of Phase 2 feedback from the U.S. Food and Drug Administration (FDA) on CANYON results for sevasemten in Becker in the first half of 2025</li>
<li>Report data from the Phase 2 LYNX and FOX trials in the first half of 2025 and outline potential Phase 3 plans in individuals with Duchenne</li>
</ul>
Cardiovascular and Cardiometabolic Programs
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction.
<ul>
<li>Report initial CIRRUS-HCM 28-day data in the first quarter of 2025</li>
<li>Release data from the 12-week CIRRUS-HCM trial in individuals with obstructive HCM and non-obstructive HCM by the second half of 2025</li>
<li>File an investigational new drug application for a second-generation heart failure candidate</li>
<li>Select a proprietary cardiometabolic drug candidate from preclinical proof of concept data</li>
</ul>
2024 Accomplishments
Financial
<ul>
<li>Strengthened balance sheet with net proceeds of approximately $232 million from January 2024 public follow-on offering supporting our muscular dystrophy and cardiovascular programs​</li>
</ul>

Biotech

News

General

EWTX

Edgewise Therapeutics Announces 2025 Priorities, Progress In Muscular Dystrophy And Cardiac Therapies; Seeks Completion Of GRAND CANYON Recruitment For Becker Trials In Q1; Targets Phase 2 FDA Feedback On CANYON In H1; Plans Phase 3 For Duchenne

Barclays analyst Brendan Lynch maintains Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) with a Overweight and lowers the price target from $192 to $184.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Extra Space Storage, Lowers Price Target to $184

WIIM

DXCM

DexCom shares are trading higher after the company issued Q4 revenue expectations above estimates.

- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer -
- Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone -
- Nearly $14M in net proceeds raised in January 2025 through utilization of Company's ATM -
CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, and provided a corporate update.

Guidance

IMRX

Immuneering Announces 50% ORR In Phase 2a With IMM-1-104 Plus mFFX In Pancreatic Cancer, Surpassing 32% Benchmark

PLNT

Planet Fitness Ended 2024 With Total Membership Of ~19.7M, System-Wide Same Club Increased 5%

Barclays analyst Brendan Lynch maintains CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) with a Equal-Weight and lowers the price target from $54 to $50.

CUBE

Barclays Maintains Equal-Weight on CubeSmart, Lowers Price Target to $50

•&nbsp; &nbsp;Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025
•&nbsp; &nbsp;Plan to report top-line results from pivotal PEAK Phase 3 trial in 2nd-line GIST patients by end of 2025
•&nbsp; &nbsp;Plan to report top-line results from registration-directed APEX trial in AdvSM patients in 2H 2025
•&nbsp; &nbsp;Company to present at&nbsp;J.P. Morgan&nbsp;43rd annual healthcare conference tomorrow, Tuesday, January 14 at&nbsp;7:30 a.m. PT&nbsp;/10:30 a.m. ET
WALTHAM, Mass. and BOULDER, Colo., Jan. 13, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=h8rcScrlkoQ_k9yTpnBk85SSaHaxeuGKCZnvdzmqp21pZIq6UuVXvWjtbzWNl-jDdYAYs3IBRmbitMXYdb7HU2DNJtHmZW7Br7r_r69uAu-6o1sMTpApW2m7xtAkN6IYlxdVSaGrUJZOav81dHmEokHQu61LvsNOve6bkIv6--RU8_DMGluiMXcbt0DGVWlUQav7e0jy2AL59_BS8a8gYgQ6BIIc5XU-sketdOk5M-mRC7rXIonKR7Z-uk2bDbMJfQJeQXc05EL1_gBkUREG2cztmh824zEYWnpa0aaRRlUGVu6ORkilb-CCqZZlQHSZN3a5fwT4qmkBqXHEZGJbU96f9FPr5N1R7lwiDmk_fYv7RqwcBuh5eQrDSimjRd38u3Ug3vTO3_7KDRc5Vl-EVSKvdtDexZUmhEE4ZHxA2oNmSQNyMPsjvNaYajHI_SL-Prkkag5OsqJ7n3dMqPTlon8gBCIrzIzowFq72PqP2zy-jUl9v7Ilzj_nD0L7ImEe">Cogent Biosciences, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>), a biotechnology company focused on developing precision therapies for genetically defined diseases, today highlighted the company's key 2025 milestones ahead of its presentation at J.P. Morgan's 43rd annual healthcare conference.

COGT

Cogent Biosciences Announces 2025 Milestones, SUMMIT Results In NonAdvSM In July, PEAK Phase 3 In 2nd-Line GIST By Year-End, APEX In AdvSM in H2; Presenting at J.P. Morgan Healthcare Conference Tomorrow At 10:30 AM ET

ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA Submission
ANX007 First Potential Neuroprotective Therapy for Geographic Atrophy Expected to Complete Enrollment of Phase 3 ARCHER II Trial in 2H 2025
ANX1502 First Oral C1s Inhibitor On Track for Clinical Proof of Concept Data in 1Q 2025
Cash Runway into 2H 2026 to Achieve Key Milestones
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=LhDaugW6LKo6u61OPTfOI-F6dJ9td1E-b2H-tGy6O-B4KPymjiZpwQmFgVHXXvBYOZCAs1siXMnXoMlRumS9Dg==">Annexon, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced its 2025 outlook and key catalysts for its flagship programs: ANX005 in Guillain-Barré syndrome (GBS), ANX007 in geographic atrophy (GA), and oral small molecule ANX1502 for a host of diseases.

ANNX

Annexon Announces 2025 Outlook, ANX005 Targets Guillain-Barré Syndrome BLA In H1 2025, ANX007 Completes Phase 3 Enrollment For Geographic Atrophy In H2 2025, ANX1502 Seeks Clinical Data In Q1 2025; Cash Runway Extends To H2 2026

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Monday.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell in today's <a href="https://www.benzinga.com/tech/25/01/42937389/tesla-hikes-model-3-y-prices-in-canada-by-c1000-after-announcing-price-increase-in-china">pre-market trading</a>.
Tesla increased the price of all Model Y and Model 3 variants in Canada by C$1,000 (about $692).
Tesla shares declined 2.8% to $383.69 in pre-market trading
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) fell 24.8% to $4.31 in pre-market trading after gaining 9% on Friday.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 17% to $7.41 in pre-market trading after dipping 11% on Friday.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) dipped 14.5% to $4.93 in pre-market trading.</li>
<li>IonQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) fell 14.5% to $27.64 in pre-market trading.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) dipped 13.4% to $2.78 in pre-market trading.</li>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) declined 13.4% to $42.00 in pre-market trading. Mercury General shares dipped around 20% on Friday after the company announced it anticipates wildfire losses in Southern California to surpass $150 million in reinsurance retention levels.</li>
<li>Tredegar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>) shares tumbled 8.1% to $6.82 in pre-market trading.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) fell 4.3% to $38.36 in the pre-market trading session.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

HOOD

IONQ

LAES

QBTS

RGTI

RZLV

TSLA

Tesla, Robinhood And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Barclays analyst Anthony Powell maintains Cousins Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUZ#NYSE">CUZ</a>) with a Overweight and raises the price target from $35 to $36.

Barclays Maintains Overweight on Cousins Props, Raises Price Target to $36

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>), a global digital operator ("VEON" or, together with its subsidiaries, the "Group"), and Cohen Circle Acquisition Corp. I ("Cohen Circle"), a special purpose acquisition company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCIRU#NASDAQ">CCIRU</a>), today announced the signing of a letter of intent ("LOI") to enter into a business combination with the aim of indirectly listing Kyivstar, VEON's digital operator in Ukraine, on the Nasdaq Stock Market LLC ("Nasdaq") in the United States.
Completion of this transaction would make Kyivstar the first purely Ukrainian investment opportunity to be publicly listed on a U.S. stock exchange, enabling U.S. and other international investors to participate more directly in Kyivstar's growth and the broader recovery of the Ukrainian economy.
Kyivstar is Ukraine's leading digital operator, with the country's largest mobile and fixed-line connectivity businesses that serve nearly 24 million connectivity customers. Kyivstar's portfolio of digital services includes the digital healthcare platform Helsi with a registered user base of 28 million and the entertainment streaming platform, Kyivstar TV. Kyivstar is a leading provider of enterprise services in Ukraine, supporting Ukrainian businesses with cloud, cybersecurity and AI solutions, a growing player in the software development landscape of Ukraine via Kyivstar Tech, and a preferred partner for international technology companies, having most recently signed a groundbreaking agreement with Starlink to bring direct-to-cell satellite connectivity to Ukraine to enhance the resilience of communication. &nbsp;

IPOs

CCIRU

VEON

VEON And Cohen Circle Announced LOI For Business Combination Aiming To List Kyivstar On Nasdaq

Donald Trump Jr.&#8216;s decision to join prediction market startup prediction market Kalshi as a strategic advisor reveals the growing <a href="https://www.benzinga.com/24/12/42746085/the-only-2025-market-prediction-youll-need">importance of prediction markets</a> and the fierce regulatory battles shaping their future.
What Happened: The addition of Trump Jr., according to a Wall Street Journal <a href="https://www.wsj.com/finance/regulation/prediction-markets-venue-kalshi-appoints-donald-trump-jr-as-adviser-98213149">report</a> on Monday, highlights the high stakes of prediction markets as a tool for both insight and speculation.
Kalshi gained notoriety for its real-time pricing of <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41583301/kalshi-ceo-tarek-mansour-on-the-growing-election-betting-market-a-coin-flip-with-a-bias">the U.S. presidential election</a>, proving the potential of prediction market to challenge mainstream media.
Trump Jr. himself, having used Kalshi on election night, views the market as a disruptive force. 
His involvement signals a deliberate move by Kalshi to expand its reach and influence at a time when its regulatory standing is under intense scrutiny.
This appointment comes as Kalshi aggressively expands its business, aiming to forge new partnerships and reach a broader audience.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42942291/exclusive-bitcoin-tumbling-but-bull-market-top-isnt-in-yet-experts-say">EXCLUSIVE: Bitcoin Tumbling, But Bull Market Top Isn&#8217;t In Yet, Experts Say</a>
Why It Matters: While Kalshi is making waves with its U.S. platform, it is competing against offshore rival Polymarket, which is not registered with the CFTC but is also looking to expand its reach to the U.S. market.
These markets now draw in everyday investors alongside established firms such as Susquehanna, which are actively trading these contracts, showing its mainstream appeal.
Kalshi offers contracts on potential policies of a Trump administration, including controversial subjects like the number of hypothtetical deportations.
This is indicative of the increasingly risky nature of individual investments that are now available in mainstream markets, including crypto and daily option bets. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42940555/bitcoin-slides-to-91000-ahead-of-upcoming-key-inflation-data">Bitcoin Slides To $91,000 Ahead Of Upcoming Key Inflation Data</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Donald Trump Jr. Joins Kalshi Prediction Market As Strategic Advisor

$3,000,000,000 aggregate principal amount of its senior notes, consisting of $1,100,000,000 aggregate principal amount of its 4.800% senior notes due2028 (the "2028 Notes"), $800,000,000 aggregate principal amount of its 5.050% senior notes due 2030 (the "2030 Notes") and $1,100,000,000aggregate principal amount of its 5.200% senior notes due 2032 (the "2032 Notes" and together with the 2028 Notes and the 2030 Notes, the "Notes").The Notes were registered under the Securities Act of 1933, as amended (the "Act"), pursuant to the Company's registration statement on FormS-3ASR &nbsp;(File No. 333-280715) &nbsp;(the "Registration Statement"), dated July 8, 2024. On January 8, 2025, the Company filed with the U.S. Securities andExchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), containing the final terms of the Notes pursuant to Rule424(b)(2) of the Act. The Notes were sold pursuant to the Underwriting Agreement and were issued pursuant to the Prospectus Supplement. The Notesare governed by the Indenture, dated July 12, 2024 (the "Base Indenture"), between the Company and Wilmington Trust, National Association, astrustee (the "Trustee"), as supplemented by the Supplemental Indenture No. 3, dated January 10, 2025 (the "Supplemental Indenture"), between theCompany and the Trustee.The 2028 Notes will mature on April 15, 2028, the 2030 Notes will mature on April 15, 2030 and the 2032 Notes will mature on April 15, 2032.The Notes are unsecured, unsubordinated obligations of the Company and will rank equally in right of payment with all of the Company's existing andfuture unsecured, unsubordinated indebtedness, liabilities and other obligations. The Notes will not be guaranteed by any of the Company's subsidiariesand will therefore be structurally subordinated to the indebtedness and other liabilities of the Company's subsidiaries.The Company expects to use the net proceeds received from the issuance of the Notes for general corporate purposes and for repayment of debt

Offerings

AVGO

Broadcom Issues $3B Senior Notes, $1.1B At 4.8% Due 2028, $800M At 5.05% Due 2030, $1.1B At 5.2% Due 2032; To Use Proceeds For General Corporate Purposes And Debt Repayment

AAON's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NYSE">AAON</a>) short percent of float has fallen 7.07% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AAON Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736775923_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AAON has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AAON's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AAON's peer group average for short interest as a percentage of float is 3.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

AAON

Looking Into AAON's Recent Short Interest

EQT's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) short percent of float has fallen 11.76% since its last report. The company recently reported that it has 17.05 million shares sold short, which is 3.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>EQT Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736775918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for EQT has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing EQT's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, EQT's peer group average for short interest as a percentage of float is 6.69%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(EQT) - Analyzing EQT's Short Interest

Tradeweb Markets's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TW#NYSE">TW</a>) short percent of float has risen 16.36% since its last report. The company recently reported that it has 1.49 million shares sold short, which is 1.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tradeweb Markets Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736775912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tradeweb Markets has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tradeweb Markets's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tradeweb Markets's peer group average for short interest as a percentage of float is 2.91%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Tradeweb Markets's Recent Short Interest

Fourth Quarter &amp; Year-End 2024 Update
For the fourth quarter of 2024, the Company acquired 63 properties leased to the USPS for approximately $30.7 million, excluding closing costs, comprising approximately 176,000 net leasable interior square feet. These acquisitions were completed at a weighted average capitalization rate of approximately 7.5%.
The Company's owned portfolio was 99.6% occupied with 1,703 properties across 49 states and one territory with approximately 6.4 million net leasable interior square feet and a weighted average rental rate of $10.60 per occupied leasable square foot based on rents in place as of December 31, 2024. The weighted average rental rate consisted of $12.81 per occupied leasable square foot on last-mile and flex properties, and $3.83 on industrial properties.
In November 2024, the Company drew $10.0 million on the term loan maturing in February 2028. In connection with the draw, the Company entered into an interest rate swap that effectively fixed the interest rate through February 2028 at a current rate of 5.55%. The proceeds from the draw were used to repay the outstanding balance on the revolving credit facility.
At the end of 2024, 95% of the Company's debt outstanding was set to fixed rates and $136 million of the Company's senior unsecured revolving credit facility was undrawn. The weighted average interest rate of the Company's total debt outstanding was 4.35%.
During the quarter, the Company issued through its at-the-market offering program 185,445 shares of common stock at an average gross sales price of $14.57 per share. In addition, the Company issued 171,414 common units in its operating partnership as part of the consideration for property acquired during the quarter.
As of December 31, 2024, there were 29,924,517 fully diluted shares outstanding (including securities convertible into shares of Class A common stock such as common units and long-term incentive units in the Company's operating partnership and restricted stock units) and the weighted average fully diluted share count for the fourth quarter of 2024 was 29,860,647 shares.

PSTL

Postal Realty Trust Snapped 63 Properties Leased to the USPS for ~$30.7M

SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) ("SRIVARU" or the "Company"), a manufacturer of premium electric motorcycles, today announced that it will effect a share consolidation ("Reverse Share Split") of its ordinary shares at a ratio of 50-for-1, effective as of 12:00 am on January 15, 2025 (the "Effective Time"), in order to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5450(a)(1). The Company's ordinary shares ("Ordinary Shares") are expected to begin trading on a Reverse Share Split adjusted basis on Nasdaq as of the open of trading on January 15, 2025, under the existing ticker symbol "SVMH."

Stock Split

SVMH

Srivaru Holding To Implement 50-For-1 Reverse Share Split On January 15, 2025

SPRC

SciSparc Merger Partner AutoMax Receives First Shipment Of Vehicles Manufactured By Anhui Jianghuai Automobile Group

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atricure.com%2F&amp;esheet=54176794&amp;newsitemid=20250113069942&amp;lan=en-US&amp;anchor=AtriCure%2C+Inc.&amp;index=1&amp;md5=af576ba288c3374b5fcb740b726ff649">AtriCure, Inc.</a> <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.atricure.com%2F&amp;esheet=54176794&amp;newsitemid=20250113069942&amp;lan=en-US&amp;anchor=%28Nasdaq%3A+ATRC%29&amp;index=2&amp;md5=46444f2ac51f409c3e0a388912e6aeaf">(NASDAQ:</a><a href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst &amp; Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025.
Preliminary, unaudited revenue for fourth quarter 2024 is expected to be $124.3 million, reflecting growth of approximately 17% as reported and on a constant currency basis over the fourth quarter of 2023. U.S. revenue is expected to be $101.6 million, reflecting growth of approximately 14%, and international revenue is expected to be $22.7 million, an increase of approximately 28% as reported and on a constant currency basis. Fourth quarter revenue was driven by strong growth in our cryoSPHERE&#xAE; devices for pain management, AtriClip&#xAE; devices in open chest procedures, and the EnCompass&#xAE; clamp.
Preliminary, unaudited revenue for full year 2024 is expected to be $465.3 million, reflecting growth of approximately 17% as reported and on a constant currency basis over full year 2023. As previously communicated, management expects full year 2024 positive adjusted EBITDA of approximately $26 million to $29 million, and full year 2024 adjusted loss per share of approximately $0.74 to $0.80. Adjusted EBITDA, adjusted loss per share and constant currency revenue growth are non-GAAP measures. AtriCure will provide a reconciliation of non-GAAP measures to the related GAAP measure in the release of audited 2024 results. Management will discuss financial results on the fourth quarter and full year 2024 conference call in February.

ATRC

AtriCure Announces Q4 2024 Preliminary Revenue Of $124.3M, Up 17%, And FY Revenue Of $465.3M, U.S. Revenue Up 14% To $101.6M, International Revenue Increased 28% To $22.7M; Forecasted 2024 Adjusted EBITDA Is $26M-$29M And Adjusted Loss Per Share Is $0.74-$0.80

Linkers Industries announces pricing of initial public offering and listing on Nasdaq

U.S. IPO Weekly Recap: ServiceTitan Launches As Small Issuers Slip Through The IPO Window

Chinese digital textbook provider Jinxin Technology and San Jose education technology provider zSpace made their public debuts this week, as another slow IPO year approaches its end.

Jinxin Technology, ZSpace Make Public Debuts

10:38 EST Linkers Industries (LNKS) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...

Linkers Industries Ltd trading resumes

10:33 EST Linkers Industries (LNKS) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...

Linkers Industries Ltd trading halted, volatility trading pause

12:04 EST Linkers Industries (LNKS) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...

11:54 EST Linkers Industries (LNKS) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...

GTSG

JUNS

LNKS

NAMI

SPHA

SPHAU

SVCCU

TAVI

TAVIU

TSX:SYH

TTAN

ZSPC

Press Releases

Linkers Industries Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq

Linkers Industries Limited Announced Closing of Initial Public Offering

Advent Technologies Holdings, Inc. - Class A Common Stock

Advent Technologies Hldgs

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

Linkers Industries

Linkers Industries (LNKS) Forecast

Linkers Industries (NASDAQ:LNKS) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga